Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Experience of Colistin-Glycopeptide Combination in Critically Ill Patients Infected with Gram-Negative Bacteria
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 58, Issue 2, Pages 851-858
Publisher
American Society for Microbiology
Online
2013-11-26
DOI
10.1128/aac.00871-13
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel 16S rRNA Methyltransferase RmtH Produced by Klebsiella pneumoniae Associated with War-Related Trauma
- (2013) Jessica A. O'Hara et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Surviving Sepsis Campaign
- (2013) R. Phillip Dellinger et al. CRITICAL CARE MEDICINE
- Treatment of carbapenem-resistantKlebsiella pneumoniae: the state of the art
- (2013) Nicola Petrosillo et al. Expert Review of Anti-Infective Therapy
- In VitroSynergy of Colistin Combinations against Colistin-Resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae Isolates
- (2012) Céline Vidaillac et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
- (2012) M. Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- High-Dose, Extended-Interval Colistin Administration in Critically Ill Patients: Is This the Right Dosing Strategy? A Preliminary Study
- (2012) L. Dalfino et al. CLINICAL INFECTIOUS DISEASES
- High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality
- (2012) A. Capone et al. CLINICAL MICROBIOLOGY AND INFECTION
- Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients
- (2012) J. Cohen JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In VivoEfficacy of Glycopeptide-Colistin Combination Therapies in aGalleria mellonellaModel ofAcinetobacter baumanniiInfection
- (2011) M. Hornsey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients
- (2011) F. Kontopidou et al. CLINICAL MICROBIOLOGY AND INFECTION
- In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii
- (2011) D. W. Wareham et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii
- (2010) N. C. Gordon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Management of antibiotic resistance in the intensive care unit setting
- (2010) Nicola Petrosillo et al. Expert Review of Anti-Infective Therapy
- Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria
- (2009) D. Plachouras et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center
- (2009) Joshua D. Hartzell et al. CLINICAL INFECTIOUS DISEASES
- Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case-control study
- (2009) Dimitrios K. Matthaiou et al. CRITICAL CARE MEDICINE
- International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
- (2009) Jean-Louis Vincent JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More